J. Chaim

发表

Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.

H. Hricak, P. Russo, O. Akin, 2013, Radiology.

Cancer Susceptibility Mutations in Patients With Urothelial Malignancies.

Kenneth Offit, Barry S Taylor, Vignesh Ravichandran, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temporal changes in MRI appearance of the prostate after focal ablation

H. Hricak, O. Akin, J. Chaim, 2018, Abdominal Radiology.

Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis

Harini Veeraraghavan, Evis Sala, Diana Feier, 2017, European Radiology.

Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.

M. Kattan, H. Hricak, J. Chaim, 2021, Radiology.

Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.

R. Motzer, J. Chaim, E. Jonasch, 2019, European journal of cancer.

Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes.

L. Schwartz, P. Russo, O. Akin, 2012, Radiology.

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

M. Berger, R. Motzer, V. Reuter, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.

J. Chaim, I. Ostrovnaya, M. Voss, 2015, The oncologist.

Programmatic Implementation of a Custom Subspecialized Oncologic Imaging Workflow Manager at a Tertiary Cancer Center.

H. Hricak, J. Chaim, H. Vargas, 2022, JCO clinical cancer informatics.

Bladder Cancer Imaging

J. Chaim, Y. Lakhman, M. Sohn, 2013 .

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

M. Berger, J. Wolchok, J. Chaim, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

R. Motzer, J. Chaim, A. Hakimi, 2020, Journal for immunotherapy of cancer.

Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial

R. Motzer, V. Reuter, J. Chaim, 2020, Cancer.

A phase II trial of durvalumab and tremelimumab in metastatic, non‐urothelial carcinoma of the urinary tract

J. Chaim, I. Ostrovnaya, G. Iyer, 2020, Cancer medicine.

Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes

R. Motzer, J. Chaim, A. Hakimi, 2017, Clinical genitourinary cancer.

DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC).

J. Wolchok, J. Chaim, I. Ostrovnaya, 2017 .

Preoperative Prostate MRI: A Road Map for Surgery.

O. Akin, J. Chaim, B. Ehdaie, 2018, AJR. American journal of roentgenology.

Associations between body composition features and clinical outcomes in metastatic clear cell renal cell carcinoma patients treated with immune checkpoint blockade.

R. Motzer, O. Akin, J. Chaim, 2022, Clinical Cancer Research.

Assessment of vena caval perforation by the option retrievable filter: CT imaging analysis of 276 filters

J. Chaim, E. Petre, J. Durack, 2015 .

MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy.

M. Kattan, H. Hricak, J. Chaim, 2022, Clinical genitourinary cancer.

Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (IO) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts).

R. Motzer, J. Chaim, A. Hakimi, 2019, Journal of Clinical Oncology.

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer.

J. Chaim, R. Motzer, M. Voss, 2023, European Urology Oncology.